UGI Corporation (UGI) Hits Fresh High: Is There Still Room to Run?
The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 7, 2025, UGI reported EPS of $2.21 versus consensus estimate of $1.8.
For the current fiscal year, UGI is expected to post earnings of $3.13 per share on $7.81 billion in revenues. This represents a 2.29% change in EPS on a 8.36% change in revenues. For the next fiscal year, the company is expected to earn $3.23 per share on $8.81 billion in revenues. This represents a year-over-year change of 3.19% and 12.76%, respectively.
While UGI has moved to its 52-week high in the recent past, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
UGI has a Value Score of A. The stock's Growth and Momentum Scores are B and B, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 11.7X current fiscal year EPS estimates, which is not in-line with the peer industry average of 16.3X. On a trailing cash flow basis, the stock currently trades at 5.6X versus its peer group's average of 8.1X. Additionally, the stock has a PEG ratio of 2.24. This is good enough to put the company in the top echelon of all stocks we cover from a value perspective, making UGI an interesting choice for value investors.
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, UGI currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if UGI passes the test. Thus, it seems as though UGI shares could still be poised for more gains ahead.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UGI Corporation (UGI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BCKIY or STRL: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Engineering - R and D Services sector have probably already heard of Babcock International Group PLC (BCKIY) and Sterling Infrastructure (STRL). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Currently, Babcock International Group PLC has a Zacks Rank of #2 (Buy), while Sterling Infrastructure has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that BCKIY has an improving earnings outlook. But this is just one piece of the puzzle for value investors. Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels. Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use. BCKIY currently has a forward P/E ratio of 17.68, while STRL has a forward P/E of 30.57. We also note that BCKIY has a PEG ratio of 0.63. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. STRL currently has a PEG ratio of 2.04. Another notable valuation metric for BCKIY is its P/B ratio of 8.53. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, STRL has a P/B of 9.68. These metrics, and several others, help BCKIY earn a Value grade of B, while STRL has been given a Value grade of D. BCKIY has seen stronger estimate revision activity and sports more attractive valuation metrics than STRL, so it seems like value investors will conclude that BCKIY is the superior option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Babcock International Group PLC (BCKIY) : Free Stock Analysis Report Sterling Infrastructure, Inc. (STRL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
2 hours ago
- Yahoo
Is Applied Materials (AMAT) Stock Outpacing Its Computer and Technology Peers This Year?
For those looking to find strong Computer and Technology stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Applied Materials (AMAT) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Applied Materials is one of 606 companies in the Computer and Technology group. The Computer and Technology group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Applied Materials is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for AMAT's full-year earnings has moved 1.2% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Based on the most recent data, AMAT has returned 10.7% so far this year. In comparison, Computer and Technology companies have returned an average of 9.1%. This shows that Applied Materials is outperforming its peers so far this year. Adyen N.V. Unsponsored ADR (ADYEY) is another Computer and Technology stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14.7%. Over the past three months, Adyen N.V. Unsponsored ADR's consensus EPS estimate for the current year has increased 2.3%. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Applied Materials is a member of the Electronics - Semiconductors industry, which includes 44 individual companies and currently sits at #92 in the Zacks Industry Rank. On average, this group has gained an average of 15.1% so far this year, meaning that AMAT is slightly underperforming its industry in terms of year-to-date returns. On the other hand, Adyen N.V. Unsponsored ADR belongs to the Internet - Software industry. This 174-stock industry is currently ranked #79. The industry has moved +17.6% year to date. Investors interested in the Computer and Technology sector may want to keep a close eye on Applied Materials and Adyen N.V. Unsponsored ADR as they attempt to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Applied Materials, Inc. (AMAT) : Free Stock Analysis Report Adyen N.V. Unsponsored ADR (ADYEY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
IDEXX Laboratories, Inc. IDXX posted second-quarter 2025 earnings per share (EPS) of $3.63, up 48.8% year over year. The figure surpassed the Zacks Consensus Estimate by 9.67%. Comparable constant-currency EPS of $3.50 improved 16.7% year over year. IDEXX's Q2 Revenues Quarterly revenues increased 10.6% year over year (up 9% organically) to $1.11 billion. The reported figure topped the Zacks Consensus Estimate by 4.01%. This year-over-year upside was primarily driven by Companion Animal Group ("CAG") Diagnostics' recurring revenue growth of 9% on a reported basis and 7% organically. Veterinary software, services and diagnostic imaging systems' revenues increased 9% on a reported basis (same organically). Following the earnings announcement, IDXX shares gained 9.2% in the pre-market trading today. IDEXX's Q2 Revenue Analysis by Segments IDEXX derives revenues from four operating segments: CAG, Water, Livestock, Poultry and Dairy ('LPD'), and Other. CAG's revenues rose 10.9% year over year on a reported basis and 9.7% on an organic basis to $1.02 billion. The Water segment's revenues increased 9.1% year over year on a reported and 8.4% on an organic basis to $51 million. For the second quarter, LPD revenues jumped 4.8% reportedly and 2.6% on an organic basis to $31.77 million. Revenues from the Other segment increased 0.1% on a reported basis and on an organic basis to $4.2 million. IDEXX's Margin Performance The gross profit rose 12.2% to $694.7 million. The gross margin expanded 92 basis points (bps) to 62.6% despite a 7.9% rise in the cost of revenues. Sales and marketing expenses surged 12.9% to $161.1 million. G&A expenses fell 37.2% to $99 million. R&D expenses jumped 11.6% to $61.9 million. The operating profit in the reported quarter rose 541.4% year over year to $373.1 million. The operating margin in the quarter expanded 734 bps to 33.6%. IDEXX's Financial Position IDEXX exited the second quarter with cash and cash equivalents of $164.6 million compared with $164 million at the end of the first quarter. Total debt (including the current portion) was $423.7 million compared with $449.8 million at the end of the first quarter. Cumulative net cash provided by operating activities was $423.7 million compared with $446.9 million in the prior-year period. IDEXX's 2025 Guidance IDEXX provided updated guidance for 2025. Total revenues for 2025 are now expected in the range of $4,205-$4,280 million (previously $4,095-$4,210 million), indicating growth of 7.7%-9.7%% on a reported basis and 7%-9% on an organic basis. The Zacks Consensus Estimate is currently pegged at $4.15 billion. IDEXX now expects full-year EPS in the range of $12.40-$12.76 (earlier $11.93-$12.43), calling for growth of 16-20%. The Zacks Consensus Estimate for full-year EPS is currently pegged at $12.21. Our View on IDEXX IDEXX exited the second quarter of 2025 with both revenues and earnings beating estimates. The company's innovation-driven strategy delivered solid global growth. IDEXX reported a record quarterly instrument placement, including nearly 2,400 IDEXX inVue Dx placements, building on the successful launch of IDEXX Cancer Dx in North America. CAG Diagnostics' recurring revenues remained a key driver, benefiting from strong commercial execution, including net customer gains and solid price realization. The Water segment displayed solid organic growth across major regions, with strong International growth. LPD growth was led by commercial execution in North America and the Asia Pacific. Furthermore, the expansion of both margins in the quarter is highly encouraging. IDEXX's Zacks Rank & Key Picks IDXX currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Medpace Holdings MEDP, GeneDx Holdings WGS and Boston Scientific BSX. Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today's Zacks #1 Rank stocks here. MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite's 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%. GeneDx Holdings, sporting a Zacks Rank #1 at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%. WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry's 18.6% growth. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 231.40%. Boston Scientific, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%. BSX has a historical five-year earnings growth rate of 13.3% compared with the industry's 2.7% growth. The company's earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
